TL;DR
- New study finds ADHD meds may lower psychosis risk.
- Methylphenidate, like Ritalin, shows protective effects.
- Research analyzed health records of 4,000 children.
- No increased risk of psychosis with early treatment.
- Findings offer reassurance to parents of ADHD kids.
In a groundbreaking new study, researchers have discovered that the stimulant methylphenidate, commonly known as Ritalin or Concerta, might actually lower the risk of psychosis in children diagnosed with ADHD. Yes, you heard that right! For all the parents out there fretting over their child’s medication, this news could be a game-changer.
Children with attention-deficit/hyperactivity disorder (ADHD) have long been known to be at a greater risk for developing psychotic conditions like bipolar disorder or schizophrenia compared to their neurotypical peers. This has left many parents wondering if the medications prescribed to help manage ADHD symptoms could be a double-edged sword. However, this new study published in JAMA Psychiatry suggests otherwise.
Researchers from the University of Edinburgh and University College Dublin analyzed the health records of nearly 4,000 children and adolescents diagnosed with ADHD in Finland. Their findings revealed that there was no significant difference in the risk of psychosis between children treated with methylphenidate and those who were not. In fact, sustained treatment with this medication for children under the age of 13 for three to four years appeared to lower the risk of developing psychosis.
Dr. Ian Kelleher, chair of child and adolescent psychiatry at the University of Edinburgh and senior author of the study, stated, “We found overall that although we know that this group is at an increased risk of psychosis, it wasn’t to do with the medication. That risk would seem to be due to other factors.” This is a huge relief for parents who have been anxious about the potential long-term effects of ADHD medications.
https://www.youtube.com/nbcnews
Dr. Christian Kohler, a professor of psychiatry at the University of Pennsylvania, described the results as “thought-provoking and not expected.” He cautioned, however, that this doesn’t completely rule out a possible association with older age groups, particularly those diagnosed with ADHD during late adolescence or early adulthood. Kohler pointed out that there might still be a tipping point where the risk of psychosis could increase following stimulant treatment.
“What if you’re diagnosed with ADHD at 16 and 17 and you’re being put on a stimulant?” he pondered. This raises valid concerns about the timing of treatment and the potential for cognitive dysfunction in later adolescence. Kohler also suggested that the medication dose and the stability of the patient’s condition could play critical roles in whether stimulants are protective or problematic.
https://www.tiktok.com/@nbcnews?lang=en
Interestingly, Dr. Jeffrey Newcorn, director of the division of ADHD and learning disorders at the Icahn School of Medicine at Mount Sinai, noted that while this study shines a light on the safety of methylphenidate, it doesn’t dismiss the risks associated with other ADHD medications, particularly amphetamines. Research has shown that patients prescribed amphetamines are at a higher risk of developing psychosis compared to those receiving methylphenidate.
So, what does this mean for parents? It’s a glimmer of hope in the often murky waters of ADHD treatment. As Dr. Newcorn put it, “It’s reassuring that the risk of a serious lifelong psychotic disorder is not increased by [this] medication.” For families navigating the complexities of ADHD, this study offers a much-needed sigh of relief.
As we continue to unravel the mysteries of mental health and medication, one thing is clear: understanding the implications of ADHD treatment is crucial, and this study is a step in the right direction. With more research needed, let’s keep our fingers crossed for further insights that can help families make informed decisions about their children’s health.